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Background
The JAK2V617F mutation has been associated with constitutive and enhanced activation
of neutrophils, while no information is available concerning other leukocyte subtypes. 
Design and Methods
We evaluated correlation of JAK2V617F mutation with the count of circulating basophils,
the number of activated CD63+ basophils, their response in vitro to agonists as well as the
effects of a JAK2 inhibitor.
Results
We found that basophil count was increased in patients with JAK2V617F -positive myelo-
proliferative neoplasms, particularly in polycythemia vera (PV), and was correlated to the
V617F burden. The burden of V617F allele was similar in PV neutrophils and basophils,
while total JAK2 mRNA content was remarkably greater in the latter; however, the con-
tent of JAK2 protein in basophils was not increased. Higher number of CD63+ basophils
was found in PV patients compared to healthy subjects and patients with ET or PMF and
was correlated to the V617F burden. Ultrastructurally, PV basophils contained an increased
number of granules, most of which were empty suggesting cell degranulation in vivo. Ex-
vivo experiments revealed that PV basophils were hypersensitive to the priming effect of
IL-3 and to f-MLP-induced activation; pre-treatment with a JAK2 inhibitor reduced PV
basophil activation. Finally, we found that the number of circulating CD63+ basophils was
significantly greater in patients suffering from aquagenic pruritus, who also showed high-
er V617F allele burden. 
Conclusions
These data indicate that constitutively activated and hypersensitive basophils circulate at
increased number in PV, underscoring a role of JAK2V617F in their abnormal function
and, putatively, in pathogenesis of pruritus.
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Introduction    
The JAK2V617F mutated allele is present in virtually
all patients with PV and in about 60% of those with
essential thrombocythemia (ET) and primary myelofi-
brosis (PMF), that are the other two main clinical enti-
ties comprised within the group of myeloproliferative
neoplasms (MPNs).1 The presence of the mutation,
and/or the burden of JAK2V617F allele, have been
found to correlate with defined laboratory abnormali-
ties and clinical features in the different MPNs.2 In most
of the studies performed in PV patients an allele burden
greater than 50% was found to correlate with leukocy-
tosis and higher hemoglobin level, lower platelet count,
presence and degree of splenomegaly, occurrence of
aquagenic pruritus and higher rate of transformation to
myelofibrosis.2
JAK2V617F is a constitutively phosphorylated tyro-
sine kinase whose expression in cytokine-dependent
cell lines conferred cytokine independence and cytokine
hypersensitivity through the constitutive activation of
STAT5, Akt and ERK-dependent pathways.3,4 The adop-
tive transfer of marrow cells transduced with a retro-
virus expressing JAK2V617F in irradiated recipient mice
invariably resulted in the development of erythrocyto-
sis,5-9 eventually accompanied by leukocytosis,
splenomegaly and later changes suggestive of myelofi-
brotic transformation.6-9 Presence and burden of
JAK2V617F correlated with endogenous erythroid
colony formation in PV patients10,11 and the expression of
mutated JAK2 in mice induced Epo-independent
growth in vitro.7,9 Modification in the design of gene
expression in murine models also resulted in an ET-like
phenotype,12,13 overall indicating that the JAK2V617F
mutation is an integral component of the myeloprolifer-
ative process that underlies the different MPNs.
An unique gene expression profile has been associat-
ed with the presence and/or the burden of V617F allele
in neutrophils; among involved genes there were some
associated with neutrophil activation, such as PRV-114,17
and the gene encoding leukocyte alkaline phosphatas.18
The constitutively activated status of circulating neu-
trophils associated with the mutated JAK2, together
with enhanced activation of platelets and their hyper-
responsiveness to agonists,19,20 possibly contribute to the
thrombotic tendency of PV.21 On the other hand, infor-
mation concerning functional relevance of the
JAK2V617F mutation in other leukocyte subtypes,
eosinophils and basophils, are not yet available. In this
manuscript, we provide evidence that basophils circu-
late in an autonomously activated status at higher than
normal level in PV patients, display ex-vivo hypersensi-
tivity to agonists and that these abnormalities are cor-
rected by treatment with a JAK2 inhibitor. 
Design and Methods
Patients
This study involved a total of 78 PV patients in whom
diagnosis satisfied the WHO criteria;22 for comparison,
we also included 70 patients with ET and 22 with PMF
(all according to WHO criteria), and 7 subjects with
reactive forms of hypoxic erythrocytosis. Most PV
patients were under phlebotomy, but all patients were
chemotherapy-free, at the time of blood sampling.
Thirty-four healthy volunteers were included as con-
trols. The study was approved by local Ethical
Committee and an informed consent was obtained.
Flow cytometry analysis of activated basophils 
Circulating CD63+/CD123+/HLA-DR- basophils were
enumerated using 100 µL of eparin-anticoagulated
peripheral blood (PB), promptly put in ice after sam-
pling; antibodies were from Becton Dickinson (San Jose,
CA, USA). At least 200,000 events were acquired on a
FACScan flow cytometer; results were expressed both
as the percentage of gated basophils expressing CD63
and as the absolute number of CD63+ basophils by nor-
malizing to total basophil count. CD63 expression level
was calculated as the ratio of geometric mean fluores-
cence intensity (MFI) with isotype control antibody. 
Purification of basophils and granulocytes 
Basophils were purified from PB using a negative-
depletion immunomagnetic procedure (Miltenyi
Biotech; Gladbach, Germany). Purity of the isolated
basophil preparations was checked by flow cytometry
after labelling with PE-CD123/PerCP-HLA-DR mono-
clonal antibodies (Becton-Dickinson); median purity
was 81%, ranging from 75 to 86%. Neutrophils were
obtained after centrifugation of PB on a Ficoll density
gradient; by visual inspection of cytosmears, neu-
trophils were greater than 95-97% of the cells while
basophils were virtually absent from these cell suspen-
sions. 
Analysis involving DNA and RNA
Determination of the JAK2V617F burden in density-
gradient purified neutrophils and immuno-selected
basophils was performed using real-time PCR.16 For dis-
criminating between un-mutated and V617F-mutated
JAK2 mRNA in purified neutrophils or basophils we
employed an ARMS technique, as previously
described.16 Quantification of the level of total (mutated
plus wild-type) JAK2 mRNA was accomplished with
TaqMan® Gene Expression Assays (HS-00234567_m1;
Applied Biosystems, Foster City, CA, USA) by means of
ABI PRISM 7300 HT Sequence Detection System. Gene
expression profiling was achieved using the
Comparative cycle threshold (CT) method of relative
quantitation using VIC-labeled RNaseP probe as the
housekeeping gene (Applied Biosystems) (DCT). 
Determination of JAK2 protein content in basophils
and granulocytes
Neutrophils and basophils were purified from PB as
described above; to obtain enough protein amount for
western blotting analysis, basophils and neutrophils
from three PV patients with greater than 50% V617F
allele burden and three normal controls were pooled.
Cell lysates were resolved on a 10% acrylamide
SDS/PAGE and blotted onto a PVDF membrane
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(Immun-Blot PVDF Membrane, BioRad, Hercules, CA).
Blots were probed with antibodies specific for JAK2
(anti-Jak2 rabbit antibody, Cell Signaling Technology,
Danvers, MA, USA) and tubulin (β-Tubulin mouse
monoclonal IgG, Santa Cruz Biotechnology, Santa
Cruz, CA), followed by peroxidase labelled secondary
antibodies, and revealed with ECL (Amersham ECL
Western Blotting Detection Reagent, Ge Healthcare,
Little Chalfont, UK). To measure cellular JAK2 protein
content we also employed a FACS-based technique.
Samples of PB from PV patients and healthy controls
were incubated with CD45 PerCP (Becton Dickinson,
USA) and CD11c PE (BD Pharmingen, USA) for neu-
trophils or CD45 PerCP and CD203c PE for basophils at
room temperature for 15 minutes in the dark. Samples
were fixed by mixing one volume of blood with 20 vol-
umes of  pre-warmed 1X BD Phosflow Lyse/Fix Buffer
(Becton Dickinson, USA) at 37°C for 10 minutes. After
washing twice with BD PharmingenTM Stain Buffer
(Becton Dickinson, USA), cells were permeabilized by
adding 1 mL of BDTM Phosflow Perm Buffer III (Becton
Dickinson, USA)  followed by an anti-JAK2 rabbit anti-
body at room temperature for 30 minutes in the dark,
washing, incubated with Alexa Fluor 488 goat anti-rab-
bit IgG (Invitrogen, USA), and finally resuspended in the
same buffer prior to flow cytometric analysis using
FacsCan (Becton Dickinson, USA). Data analysis was
performed using WinMDI software (v2.9; http://
facs.scripps.edu/software.html).
Ex vivo stimulation of basophils 
PB samples were incubated with varying concentra-
tions of recombinant hIL-3 and/or N-Formyl-Met-Leu-
Phe (fMLP) peptide and the appearance of CD63 on the
membrane of CD123+/HLA-DR- gated basophils was
measured. In some experiments, the specific JAK2
inhibitor AZD1480 (kindly provided by Astra Zeneca Ltd)
was used. PB samples (100 µL volumes) collected in pre-
servative-free heparin were processed immediately after
sampling. Samples were equilibrated at 37°C in a water
bath in polypropilene tubes for 15 min; then, rhIL-3 (from
0.1 to 10 ng/mL; Peprotech Inc, Rocky Hills, NJ) and fMLP
peptide (from 0.01 to 0.04 µM; Sigma, Milano, I) were
sequentially added, and an additional 15 min incubation
was performed. Control tubes containing no addition
(blank), rhIL-3 or fMLP alone (controls) were also pre-
pared. At the end of incubation, samples were put on ice
for 5 min, and basophils were labelled with 20 µL of
FITC-CD63, PE-CD123 and PerCP anti-HLA-DR anti-
body cocktail (BD FastImmune, Becton-Dickinson) for 15
min at room temperature. Red blood cells were lysed
with 2 mL of 1x FACSTM Lysing solution  (Becton-
Dickinson) for 15 min at room temperature and nucleat-
ed cells were washed twice with 1-2 ml of PBS. 
Quantification  of CD63+ cells was performed in the
basophil gate by acquiring at least 200,000 events; each
experimental point was performed in duplicate. For inhi-
bition of JAK2-mediated responses, cell samples were
pre-incubated for 15 min at 37°C with the JAK2 inhibitor
AZD1480  using two different concentrations (400 and
4,000 nM); then, optimal amount of rhIL-3 (10 ng/mL)
and f-MLP peptide (0.04 mM) were added, and the cells
were analyzed as described above.
Trasmission electron microscopy (TEM)
The enriched PB mononuclear cell fraction, obtained
after centrifugation over a Ficoll-Hypaque gradient
(Lymphoprep, Nycomed Pharma; Oslo, Norway), was
processed for trasmission electron microscopy (TEM)
by fixing in 2.5% glutaraldehyde in 0.1 M cacodylate
buffer, pH 7.6, for 2 hr at 4°C and postfixing in osmium
tetroxide for 60 min at 4°C. The samples were then
dehydratated in alcohol at progressively higher concen-
trations and embedded in Spurr resin (Poliscience,
Warrington, PA, USA). Consecutive thin and ultrathin
sections were cut using a Reichert ultramicrotome.
Ultrathin sections were collected on 200-mesh copper
grids, counterstained with uranyl acetate and lead cit-
rate, as described.23 Both the total number of granules
per cell, and the number of empty granules, were enu-
merated in at least 10 basophils/sample.
Statistical analysis
Comparison between groups was performed by the
Mann-Whitney U or Fisher test as appropriate, using
the SPSS software (StatSoft, Inc., Tulsa, OK,
http://www.statsoft.com), GraphPad InStat software
(GraphPad Software, Inc., San Diego, http://www.graph-
pad.com) or ORIGIN software (V 7.5, OriginLab
Northampton, MA, USA, http://www.originlab.com) for
computation. The analysis of correlation between
JAK2V617F allele burden and hematologic parameters
was performed according to Spearman’s rank nonpara-
metric correlation test. A P value of less than .05 was
considered to indicate statistical significance; all tests
were two-tailed. 
Results 
We studied a cohort of 78 JAK2V617F-mutated PV
patients in whom the level of mutated allele burden
ranged from 1 % to 100%, with a median value of 56%;
their main hematological and clinical features are
reported in Table 1. About half of the patients referred a
history of aquagenic pruritus, that was considered by
the referring physician as possibly related to the under-
lying hematologic disease after careful exclusion of any
other known potential cause, and when it was
described from the patient as diffuse, non-occasional,
itching exacerbated by water contact and resistant to
common anti-histamine drugs, whenever used. Due to
the design and objectives of the study, the percentage of
patients with aquagenic pruritus can result over-esti-
mated and does not reflect the overall occurrence of this
symptom in an unselected population of PV patients.
We also evaluated 70 ET patients, 62% of whom were
JAK2V617F mutated (mean allele burden was 29%) and
17 patients with PMF (13 of whom had the V617F allele,
mean allele burden was 49%).
First, we found that mean absolute count of circulat-
ing basophils, measured by routine coulter counter, was
significantly greater than control subjects (23.5±8.7
x106/L) in patients with PV (119.8±93.8x106/L;
JAK2V617F mutation and basophils in PV
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p<0.0001), patients with ET (48.9±30.0×106/L;
p=0.0006) or with PMF (64.1±59.3×106/L; p=0.0042); on
the other hand, patients with reactive forms of erythro-
cytosis had basophil count similar to healthy subjects
(20.0±15.3×106/L; p=0.46) (Figure 1A). The basophil
count was significantly greater in patients with PV com-
pared to ET or PMF patients (p<0.0001 and =0.02,
respectively). There was also a statistically significant
difference in mean basophil count between PV patients
harboring a lower or greater than 50% V617F allele bur-
den (82.8±48.9 and 155.5±109.7×106/L, respectively;
(p=0.002) and between ET or PMF patients who were
V617F mutated or wild-type (55.9±35.8 and
39.6±19.0×106/L , respectively; p=0.04 in case of ET;
75.4±63.0 and 24.3±18.1×106/L, respectively; p=0.04 in
case of  PMF) (Figure 1A). 
We measured the burden of V617F allele in immuno-
magnetically selected basophils and in density-gradient
purified neutrophils from 15 PV patients; we found that
the two measurements were strongly correlated each to
the other (r=0.90; Figure 1B), suggesting that the relative
proportion of wild-type and mutated JAK2V617 allele in
the two leukocyte subtypes was comparable. On the
other hand, we observed that the content of total JAK2
mRNA was significantly greater in PV basophils com-
pared not only to normal basophils (P=.04) or neu-
trophils (p=0.01; n=12 subjects) but also to the concur-
rently purified PV neutrophils (p=0.00007) (Figure 1C).
Such an increase was not due to a preferential transcrip-
tion or increased stability of mutated JAK2 mRNA in PV
basophils, since the relative proportion of the wild-type
and V617F-mutated mRNA transcripts was consistent
with the results of quantitative (not shown in detail). To
evaluate whether also the content of JAK2 protein was
increased in PV basophils, we employed a FACS-based
analysis in three PV patients and three healthy controls,
and western blotting technique; in the latter instance,
we pooled purified basophils and granulocytes from
three additional PV patients and three healthy controls
to cope with the low protein recovered. However, using
both approaches we were unable to document signifi-
cantly increased JAK2 content in basophils (Figure 1D
L. Pieri et al. 
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Table 1. Clinical and hematological features of the patients with
polycythemia vera (n=78)  included in the study.
Demographic characteristic
Median age, years (range) 62 (17-84)
Male sex, no. (%) 37 (47)
Laboratory and clinical features
White cell count,  ×106/L
Mean 11.1±4.8
Median (range) 9.6 (4.6-28.3)
Hemoglobin,  gr/dL
Mean 15.0±1.7
Median (range) 14.8 (13.3-18.9)
Hematocrit,  %
Mean 47.5±4.7
Median (range) 47.4 (42.9-57.5)
Platelet count,  ×106/L
Mean 499.0±226.0
Median (range) 468.0 (132-1,101)
JAK2V617F mutated pts, no. (%) 78 (100)
1-50% 35 (45)
50-100% 43 (55)
Median JAK2V617F allele burden, % (range) 56 (1-100)
Pruritus, no. (%) 38 (49)
Arterial or venous thrombosis, no. (%) 24 (31)
Palpable splenomegaly, no. (%) 48 (62)
Figure 1. (Panel A) The absolute count of peripheral blood
basophils in PV patients (n=78) divided according to their
JAK2V617F allele burden lower or greater than 50%; patients with
ET or PMF, control subjects (Ctr) or subjects with reactive forms of
erythrocytosis (RE) are also shown. Boxes represent the interquar-
tile range that contains 50% of the subjects, the horizontal line in
the box marks the median, the small square inside indicates the
mean value, and bars show the range of values. The P value of the
differences among different patient groups is shown on the right.
(Panel B) Correlation between the burden of JAK2V617F allele
concurrently measured in density gradient-purified neutrophils (on
the X-axis) and immunomagnetically selected basophils (on the Y-
axis) in PV patients (n=15). (Panel C) Level of total JAK2 mRNA in
purified neutrophils and basophils from healthy control subjects
and PV patients was determined with real time PCR and
expressed as DCT after normalization to RNAseP as the house-
keeping gene. Please note that higher DCT values indicate lower
mRNA content. (Panel D) FACS analysis for intracellular JAK2
staining in neutrophils (on the left) and basophils (on the right)
using whole peripheral blood samples; for details, refer to the text.
Gray area represents unspecific fluorescence. The Y-axis indicates
mean fluorescence intensity (MFI; arbitrary units). (Panel E)
Western blot analysis of JAK2 content in neutrophils and
basophils pooled from three patients with PV (all with >50%
V617F allele) and three healthy subjects. Tubulin was used to nor-
malize protein load.  
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and E). In particular, the mean fluorescence index (MFI)
measured in PV basophils was 1,083±1,028, similar to
1,400±762  in control basophils, and 341±186 and
540±339, respectively, in PV and normal granulocytes.
Therefore, we concluded that the increased JAK2
mRNA levels in PV basophils did not result in increased
protein synthesis. 
The expression of CD63 on the outer membrane of
basophils was used as a marker of their activated status
both in vivo and in ex vivo experiments.24 We found that
mean percentage of CD63+ cells in the CD123+/HLA-
DR– basophil gate was significantly greater in PV
patients than in controls (13.0±10.5% versus 1.8±1.7%;
p=0.01), patients with ET or PMF, or patients with reac-
tive erythrocytosis (Figure 2A). The absolute number of
activated basophils in the circulation increased from
0.4±0.3×106/L in controls to 15.5±11.6×106/L in PV
patients (Figure 2B; p=0.004); the number of CD63+
basophils in ET or PMF was similar to controls (Figure
2B). Both the relative proportion and the absolute num-
ber of CD63+ basophils in the PB were correlated to the
burden of V617F allele; mean values were 15±9.5% and
21.2±10.8×106/L, respectively, in PV patients with >50%
mutated allele compared to 4.7±3.8% and
7.1±6.7×106/L in those with a mutated allele burden
<50% (p=0.02, and p=0.04, respectively; Figure 2A, 2B).
In addition, we found a significant linear regression
between the absolute number of circulating CD63+
basophils in PV and the JAK2V617F allele burden
(r=0.73, P=.008; not shown in detail). Also the CD63
MFI was significantly increased in PV patients com-
pared to control subjects (1,405±856 vs 740±145.2;
P=.04) as well as to patients with ET or PMF or subjects
with reactive erythrocytosis (Figure 2C); on the other
hand, although the mean MFI value was greater in
patients with more than 50% V617 allele (1,423±1,112)
compared to those with <50% mutated allele
(1,152±604), the difference did not reach the signifi-
cance level because of the wide scattering of data
(Figure 2C). 
We employed TEM analysis to enumerate the num-
ber of granules contained in basophils and to character-
ize their morphology; a representative image of control
and PV basophils is presented in Figure 3A. We found
that the number of granules contained in basophils of
PV patients was significantly greater than in healthy
controls (18.1±1.4 versus 10.0±1.1, respectively;
p=0.005); furthermore, the number of empty granules,
mostly of which also presented a disrupted membrane,
was significantly increased in PV compared to control
basophils (7.4±0.9 versus 0.1±0.1, respectively; p<.001)
(Figure 3B). In most instances, the cytoplasm of PV
basophils also showed abnormal electrondensity and
extensive vacuolization (Figure 3A). 
Altogether, these data suggested that the number of
activated basophils circulating in PV patients is
increased over control subjects and correlated to the
V617F allele burden; furthermore, these cells presented
morphological abnormalities compatible with ongoing
in-vivo activation and degranulation.
To evaluate possible correlations between the
JAK2V617F mutation and basophil function, we evalu-
ated their ex vivo activation by monitoring the expres-
sion of the activation marker CD63 on the cell surface;
to this end, cells were incubated with rhIL-3, known to
exert a potent priming effect mainly through the
JAK2/STAT5 pathway,25 followed by challenging with
the f-MLP peptide, that acts by binding to a het-
erotrimeric G-protein coupled receptor. We found that
at any of the three f-MLP concentrations employed
(from 0.01 to 0.04 uM) the fraction of basophils induced
to express CD63 was significantly greater in PV patients
than in controls, particularly in those having greater
than 50% mutated allele (Figure 4A). At the highest
dose of 0.04 mM f-MLP employed, there were 2.44±0.6-
fold more basophils expressing CD63 in PV compared
JAK2V617F mutation and basophils in PV
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Figure 2. The plots show the fraction of basophils expressing the
CD63 activation marker within the basophil gate (Panel A) or the
absolute count of CD63+ basophils (Panel B) in the PB of PV
patients, either all together (n=72) or divided according to their
JAK2V617F allele burden lower or greater than 50%. Patients with
ET or PMF, control subjects (Ctr) or subjects with RE are also
shown.  The mean fluorescence intensity of CD63 on the mem-
brane of gated basophils is presented in (Panel C).  
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to control samples (1.38±0.3 fold increase over base-
line); in patients with >50% mutated allele the increase
of CD63+ basophils compared to baseline was 3.3±0.2
fold (p<0.01; Figure 4A). Similarly, when basophils were
primed with varying  amounts of rhIL-3 (in the range
from 0.1 to 10 ng/mL) and then challenged with an opti-
mal amount of fMLP, the response of PV cells resulted
significantly greater than in control cells at any IL-3 dose
point (Figure 4B). Overall, these data suggested that the
response of PV basophils to the priming effect of IL-3 is
abnormally enhanced compared to control cells. To
address the role of mutated JAK2, we employed the
potent and selective JAK2 inhibitor AZD1480. This
agent was shown able to significantly reduce the ex vivo
activation of PV basophils in response to optimal
amount of f-MLP and rhIL-3 (Figure 4C); at 4.0 mM
AZD-1480, there was a 66% reduction in the fraction of
PV basophils expressing CD63. Notably, the inhibitory
effect was more pronounced in PV than control
basophils, which were not appreciably affected by the
drug. We found no meaningful correlation between
number of circulating CD63+ basophils and hematolog-
ical or clinical characteristics of PV patients, which
L. Pieri et al. 
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Figure 3. (Panel A) Representative TEM analysis of circulating
basophils in a control subject (images on the left) and a PV patient
(on the right; V617F allele burden =70%). Thin (upper panels) and
ultrathin (lower panels) sections were observed under vacuum
with an EM 109 Zeiss microscope equipped with built-in electro-
magnetic objective lenses and camera (Oberkochen, Germany).
Photographs were taken with Kodak Technical Pan film (Kodak,
Rochester, NY, USA), developed with Kodak D 19 1+4 automatic
developer and scanned with an EPSON Perfection 3200 photo-
scanner (Seiko EPSON, Nagano-ken, Japan). Original magnifica-
tion was 4,400x and 7,000x for the upper left and right panel,
respectively, and 20,000x for the lower panels. (Panel B) The
absolute number of granules contained in basophils from PV
patients (n=5) and healthy subjects (n=4) is shown (gray columns)
after enumerating at least 10 basophils/subject; the number of
those granules devoid of their electron-dense content (empty
granules) is also presented (black columns). Statistically signifi-
cant differences are reported in the plot.
Figure 4. (Panel A) Expression of the activation marker CD63 in
PB cells after being incubated ex-vivo with increasing amounts of
fMLP peptide (0 to 0.04 mM) in the presence of an optimal
amount of rhIL-3 (10 ng/mL). Results were expressed as per cent
increase of CD63+ basophils over un-stimulated cells. The mean
(±SD) values measured in control subjects (n=5; triangles) and PV
patients (n=10), either all together (dashed line; for clarity, SD is
not presented) or divided according to their V617F allele burden
(>50% (squares) or <50% (dots), n=5 each), is presented. (Panel
B) Experiments as above were performed by using increasing
amounts of rhIL-3 in the presence of a fixed dose of f-MLP peptide
(0.02mM). Only PV patients with >50% mutated V617F allele
were used in these experiments and compared to controls (n= 5
each). Results were expressed as per cent increase of CD63+
basophils over cultures containing f-MLP only. (Panel C) PB cells
from PV patients and control subjects (n= 5 each) were pre-incu-
bated with the specific JAK2 inhibitor AZD1480 at two different
concentrations, and then challenged with fMLP peptide (0.04 mM)
and IL-3 (10 ng/mL). The fraction of cells in the basophil gate
expressing CD63 was measured by FACS; results were expressed
as per cent decrease of CD63+ basophils in wells containing the
drug compared to cells without inhibitor. Only PV patients with
>50% mutated V617F allele were used in these experiments.
*p<0.05; **p<0.01.
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included splenomegaly, thrombosis, or need of
chemotherapy (not shown in detail); on the other hand,
we found that both the relative proportion and the
absolute count of circulating CD63+ basophils were sig-
nificantly higher in patients suffering from aquagenic
pruritus than in those who did not (Figure 5). Also,
according to previous reports,26,27 we found that the
V617F allele burden was significantly greater in patients
with pruritus (71±18%) than in those without
(48±19%; p=0.002).
Discussion 
To the best of our knowledge, this is the first study
addressing possible effects of the JAK2V617F mutation
in basophils from patients with PV and other MPNs.
The data presented herein suggested that: (i) the count
of basophils in the PB of MPN patients, but particularly
in those with PV and in case of JAK2V617F mutated ET
or PMF, is significantly increased over normal level. The
design of this study does not allow to conclude whether
this is actually due to an increased output from
JAK2V617F mutated basophil progenitors, increased
size of the early progenitor pool, increase survival of the
mature cells, or a combination of these. At this regard,
it is intriguing that IL-3 was recently shown to efficient-
ly protect normal basophils from apoptosis through the
activation of BCL-XL and a Pim-1 dependent pathway.28
(ii) the count of constitutively activated basophils in the
circulation, as measured by their expression of the acti-
vation marker CD63, is significantly increased in PV
patients; intriguingly, their number is associated with
the highest allele burden and with the complaint of
aquagenic pruritus. Of note, patients with ET or PMF
had count of activated basophils that did not differ sig-
nificantly from healthy subjects. Indirect support to an
in-vivo activated status of PV basophils was also provid-
ed by the findings of an increased number of empty
granules in these cells according to electron microscopy
analysis. (iii) in vitro, PV basophils showed hypersensi-
tivity to IL-3 and were hyper-responsive to the f-MPL
agonist compared to normal cells; (iv) abnormal in vitro
activation was largely prevented by treatment with a
JAK2 inhibitor. One additional findings of this study is
that the content of total JAK2 mRNA in PV basophils
was significant increased compared to PV granulocytes
as well as to control basophils, without evidence of
preferential transcription or accumulation of V617F
mutated RNA. To ascertain whether also the content of
JAK2 protein was increased in PV basophils, we per-
formed FACS analysis and western blotting; results
obtained with both techniques indicated that the pro-
tein content did not differ in PV basophils compared to
PV granulocytes or normal cells. Due to the low number
of basophils which could be recovered after immuno-
magnetic purification we have been unable to perform
experiments aiming at distinguishing between increased
JAK2 mRNA transcription from increased mRNA stabil-
ity as the mechanism(s) for the higher levels of JAK2
mRNA measured in basophils. However, it is of interest
that these findings are reminiscent of PRV-1 gene,
whose expression was found enhanced in PV granulo-
cytes without being associated with increased protein
content.29
To evaluate the activation status of circulating
basophils and their response in vitro to agonists we
measured the expression of CD63 on the basophil cell
membrane. CD63 is a tetraspanin contained in the inner
granule surface in resting basophils; its expression on
the outer cell surface correlates with basophil degranu-
lation and histamine release, and serves as a reliable
marker of allergen-induced basophil activation.24 The
effector functions of basophils are potently enhanced by
several cytokines, including IL-5, GM-CSF, nerve
growth factor; however, IL-3 is the most potent priming
cytokine for human basophils, enhancing mediator
secretion, the production of IL-4 and IL-3, the de-novo
synthesis of leukotriene C4 and granzyme B.25,30,31 IL-3,
as well as IL-5, induces JAK2 and STAT5 phosphoryla-
tion as a non-redundant mechanism for basophil activa-
tion.25 Data from ex vivo experiments meaningfully sup-
ported a hyper-sensitivity of PV basophils to functional
activators possibly ascribable to constitutive signalling
from mutated JAK2, as revealed by the priming effects
of low-dose IL-3 and enhanced response to fMLP pep-
tide, and by the inhibition produced by a potent JAK2
inhibitor.
JAK2V617F mutation and basophils in PV
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Figure 5. Plots show the percentage of basophils expressing the
CD63 activation marker (Panel A) or their absolute count (Panel
B) in the PB of PV patients according to the complaint or not of
aquagenic pruritus. 
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An intriguing finding of this study was the association
between increased number of activated basophils in the
circulation of PV patients and their complaint of aqua-
genic pruritus. Pruritus, exacerbated by contact with
water during warm bath or shower, is a typical feature
of PV reported by up to 65% of patients at diagnosis.32
It can either ante date diagnosis or appear during the
course of disease; it is poorly responsive to phlebotomy
or myelosuppressive therapy, while interferon-α,33.34 or
selective serotonin reuptake inhibitors35 can be success-
ful. Pruritus has been associated with iron deficiency,36
high leukocyte count,36 platelet activation,35 histamine
release,37,38 infiltration of derma by mononuclear cells
and eosinophils,39 and degranulation of dermal mast
cells,39,40 but underlying mechanisms remain substantial-
ly obscure. Furthermore, pruritus was more common
among patients harboring greater than 50% V617F
allele26,27,41 (and this study); accordingly, we found that
circulating activated basophils, measured by their
expression of CD63,  were significantly increased in this
category of patients. Basophils are implicated in imme-
diate hypersensitivity reactions and anaphylaxis, and
their granules contain several biogenic amines, includ-
ing histamine, which might be involved in the patho-
genesis of pruritus although no clear correlation of pru-
ritus with plasma histamine levels in PV has been
found. However, it is also possible that other non canon-
ical mediators such as leukotriene C4 or granzyme B, to
name a few,30,31 might be involved as well as in the
pathogenesis of pruritus. Furthermore, basophils can
produce and release a vast array of cytokines, such as IL-
4, IL-13 and IL-33, which facilitate recruitment and acti-
vation of other inflammatory cells (including neu-
trophils, eosinophils, mast cells); therefore, PV basophils
might not necessarily act as effector cells by themselves
in causing pruritus.31,42 Our experimental design does not
allow distinguishing among these several possibilities
and the mechanistic link between basophils and pruri-
tus requires additional investigation. At this regard, evi-
dence has been provided recently that an increased out-
put of CD34+ cell-derived mast cells in patients with
MPN plays a role in pruritogenesis possibly through the
release of prostaglandin D2 and increased levels of IL-
31.43
Overall, results of this study indicated that PV
basophils are constitutively activated and hyper-sensi-
tive to IL-3, favoring a direct role of JAK2V617F muta-
tion. They also lend support to hypothesizing that acti-
vated basophils contribute to pruritus in PV patients and
that JAK2 inhibitors might result efficacious to counter
this agonizing and treatment-insensitive symptom.
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